101001-59-6 Usage
Derivative of pyrrole
A five-membered aromatic ring with one nitrogen atom The compound is based on a pyrrole structure, which is a heterocyclic, aromatic organic compound.
1-ethyl substitution
Presence of an ethyl group attached to the first carbon of the pyrrole ring An ethyl group (C2H5) is added to the first carbon of the pyrrole, altering its chemical properties and structure.
Carbonitrile functional group
Presence of a cyano group (carbon triple-bonded to a nitrogen atom) A cyano group is attached to the second carbon of the pyrrole ring, further modifying the compound's properties.
Aromatic nature
The compound retains the aromatic character of the pyrrole ring The compound has delocalized electrons across the aromatic ring, contributing to its stability.
Potential applications
Organic synthesis, pharmaceuticals, and materials science Due to its unique structure and properties, 1H-Pyrrole-2-carbonitrile,1-ethyl-(9CI) can be used in various fields, such as creating new organic compounds, developing pharmaceutical drugs, and designing novel materials.
Structural and chemical characteristics
Specific properties and uses may vary depending on the exact structural and chemical characteristics The compound's properties and potential applications are influenced by its molecular structure and the presence of functional groups, such as the ethyl and carbonitrile groups.
Check Digit Verification of cas no
The CAS Registry Mumber 101001-59-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,0,0 and 1 respectively; the second part has 2 digits, 5 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 101001-59:
(8*1)+(7*0)+(6*1)+(5*0)+(4*0)+(3*1)+(2*5)+(1*9)=36
36 % 10 = 6
So 101001-59-6 is a valid CAS Registry Number.
101001-59-6Relevant articles and documents
Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis
Kawahata, Wataru,Asami, Tokiko,Kiyoi, Takao,Irie, Takayuki,Taniguchi, Haruka,Asamitsu, Yuko,Inoue, Tomoko,Miyake, Takahiro,Sawa, Masaaki
supporting information, p. 8917 - 8933 (2018/10/09)
Bruton's tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis. A series of novel aminotriazines were identified as highly selective inhibitors of BTK by a scaffold-hopping approach. Subsequent SAR studies of this series using two conformationally different BTK proteins, an activated form of BTK and an unactivated form of BTK, led to the discovery of a highly selective BTK inhibitor, 4b. With significant efficacy in models in vivo and good ADME and safety profiles, 4b was advanced into preclinical studies.
